Ultragenyx Pharma (RARE) Announces Significant Data from UX007 Phase 2 in LC-FAOD

November 30, 2016 8:34 AM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) announced positive 78-week data from the Phase 2 study of UX007 (triheptanoin) in patients with long-chain fatty acid oxidation disorder (LC-FAOD). The frequency and duration of major medical events were reduced significantly during treatment with UX007, and patients demonstrated improved exercise tolerance and quality of life during the study.

“The reduction in frequency and duration of hospitalizations and other major medical events suggests a clinically meaningful improvement for patients and is consistent with the data from the prior retrospective compassionate use study,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “These results are encouraging and we continue to further develop the Phase 3 study design and endpoints before meeting with regulators and initiating the study in 2017.”

Major Clinical Event Rates

The major clinical event (MCE) rate aggregates events from the 29-patient open-label Phase 2 study related to hypoglycemia, cardiomyopathy and rhabdomyolysis. For this study, events that qualified included those that led to a hospitalization, emergency room visit, or an emergency intervention at home. There was a 48.1 percent reduction (p=0.0208) in the mean annualized rate of MCEs and a 50.3 percent reduction (p=0.0284) in the mean annualized duration of all MCEs after 78 weeks of treatment, compared to the mean annualized number and duration of events in the 18 to 24 months prior to treatment with UX007.

Annualized Event Rate Annualized Duration Rate Total Events
PrePost% Change PrePost% Change PrePost% Change
All MCEs (total, n=29 patients)
All events (mean)1.6900.877 -48.1% 5.9612.964 -50.3% 7039 -44.30%
All events (median)1.3330.659 -50.6% 5.3321.244 -76.7%
All hospitalization events (mean)1.3910.652 -53.1% 5.6622.739 -51.6% 5729 -49.10%

Among the event subtypes, rhabdomyolysis was the predominant MCE and there were fewer hypoglycemia events and only a few cardiomyopathy events. There was a reduction in the mean annualized rates and total duration of all events for rhabdomyolysis, cardiomyopathy, and hypoglycemia events after initiation of treatment with UX007. These findings were generally comparable to those observed in the retrospective compassionate use study previously conducted by Ultragenyx with partial reduction in rhabdomyolysis and near complete reduction of hypoglycemia events.

Annualized Event Rate Annualized Duration Rate Total Events
PrePost% Change PrePost% Change PrePost% Change
Rhabdomyolysis
All Rhabdomyolysis events (mean)1.3030.833 -36.1% 3.9492.792 -29.3% 5537 -32.7%
Hospitalization events only (mean)1.0270.630 -38.7% 3.6742.589 -29.5% 4328 -34.9%
Hypoglycemia
All Hypoglycemia events (mean)0.3180.023 -92.8% 1.4140.023 -98.4% 121 -91.7%
Hospitalization events only (mean)0.2950.000 -100.0% 1.3910.000 -100.0% 110 -100.0%
Cardiomyopathy
All Cardiomyopathy events (mean)0.0690.021 -69.6% 0.5980.149 -75.1% 31 -66.7%
Hospitalization events only (mean)0.0690.021 -69.6% 0.5980.149 -75.1% 31 -66.7%

Exercise Tolerance

Eight patients performed the twelve minute walk test (12MWT) at baseline and at Week 60, and showed a 29.7 percent improvement (mean increase: +199.8 meters; median: 149.5; min,max: -122, 1000) from a baseline of 673.4 meters. These results demonstrate that the increase in distance walked observed at 18 weeks was maintained through 60 weeks. The cycle ergometry test at 78 weeks was inconclusive and uninterpretable due to missing data as a result of scheduling conflicts, withdrawal of consent, intercurrent illness and other factors.

Quality of Life Assessment

Health Related Quality of life was assessed in the Phase 2 study using age appropriate SF-10™ (5-17 years, n=3) and SF-12v2® (>18 years, n=5) Health Surveys. Significant improvements in the impaired physical summary measures (SF-12v2 Physical Component Summary and SF-10 Physical Health Summary) reported at the start of the study were observed after 78 weeks of treatment with UX007.

Safety/Tolerability Results

Five of the 29 enrolled patients discontinued treatment over the course of the study. One patient discontinued due to diarrhea in week 1, which resolved within a few days of discontinuation, and four patients withdrew consent (weeks 1, 8, 8, 78) for reasons not attributed to treatment with UX007.

There were no deaths. There was one previously reported treatment-related serious adverse event for moderate gastroenteritis with vomiting. This patient completed the study and maintained dosing throughout the event, which has now resolved. Overall, 19 patients (66%) had treatment-related adverse events, most of which were mild-to-moderate in nature. The most common treatment-related adverse events were diarrhea, abdominal/gastrointestinal pain, and vomiting. Some gastrointestinal events were managed by adjusting dosing or dosing with food. The most common adverse events, including those not deemed treatment-related, were diarrhea, rhabdomyolisis, vomiting, viral infections, gastrointestinal disorders, headache and fever.

Phase 2 Study Design and Baseline Characteristics

The single-arm, open-label Phase 2 study evaluated 29 pediatric and adult patients across three main symptom groups (musculoskeletal, liver/hypoglycemia, and cardiac). Patients needed to have moderate to severe FAOD with significant disease in at least one of these domains or a frequent medical events history in order to enroll. The study began with a four-week run-in period to assess baseline data while on the standard of care therapy including medium-chain triglyceride (MCT) oil, if applicable.

Twenty-five patients completed 24 weeks of treatment, at which point the acute effects of UX007 treatment on the muscular aspects of the disease were evaluated. Twenty-four patients opted to continue to be treated for a total of 78 weeks with one who withdrew consent late during this period on turning 18 years old. Safety and quality of life assessments were also measured throughout the study. These Phase 2 results are based on open-label uncontrolled treatment referenced to baseline run-in period using careful medical chart reviews for each patient, but the lack of a randomized parallel control group does limit definitive conclusions about efficacy and safety.

The majority of patients enrolled presented with musculoskeletal disease compared to a limited number who presented with liver and cardiac symptoms. Patients spanned a wide age range from ten months to 58 years old. Patients with four LC-FAOD genotypes were enrolled: twelve (41%) with VLCAD, ten (35%) with LCHAD, four (14%) with CPT-II, and three (10%) with TFP. Prior to initiating treatment with UX007, 27 of the 29 patients were on the standard of care MCT oil therapy. UX007 was then titrated to a target dose of 25-35% of total daily caloric intake.

Patients performed only the assessments that were appropriate and valid for their age when they entered the study; therefore not all patients performed all assessments included in the study design. Due to the small number of patients who completed a number of the assessments in this Phase 2 study, the results would need to be confirmed in a larger controlled study.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA, Management Comments

Add Your Comment